Novo Nordisk A/S (NVO)
After hours:
| Previous close | 91.52 |
| Open | 92.50 |
| Bid | 90.92 x 800 |
| Ask | 92.00 x 800 |
| Day's range | 90.63 - 92.57 |
| 52-week range | 50.44 - 100.88 |
| Volume | |
| Avg. volume | 3,650,538 |
| Market cap | 407.891B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | 43.30 |
| EPS (TTM) | 2.10 |
| Earnings date | N/A |
| Forward dividend & yield | 1.03 (1.13%) |
| Ex-dividend date | 18 Aug 2023 |
| 1y target est | 77.90 |
Zacks3 Stocks to Focus on as Demand for Obesity Drugs Booms
With the obesity market gaining popularity, analysts are expecting sales to increase. Pharma companies are rushing to enter the market
Motley FoolIs Novo Nordisk a Good Passive Income Stock?
Passive income investors know that when there's a business that's proven to throw off a lot of cash consistently over time, it might be a good idea to hold its shares to capture safe and reliable dividends for the long haul. Novo Nordisk (NYSE: NVO) is an obvious candidate to consider right now. Thanks to its blockbuster drug Ozempic and a pipeline that's chock-full of other potential winners, Novo Nordisk seems to have most of the makings of a great dividend stock.
- Financial Times
Obesity drugmaker’s expansion raises dominance worries for Denmark
Ozempic, a diabetes treatment that celebrities take to lose weight, and Wegovy, an anti-obesity medication, have propelled Novo Nordisk to become Europe’s most valuable company and single-handedly stopped Denmark from falling into recession. At $410bn, Novo Nordisk’s market capitalisation is now larger than Denmark’s annual GDP of $400bn last year, raising concerns among officials and business figures that the country’s fortunes have become too closely tied to a single company. “The way that we look at it is that in Denmark we have a two-speed economy: the pharmaceutical industry — and the rest,” said Thomas Harr, chief economist at Denmark’s central bank.
